Loading insider details...
Beta
Latest Form 4 (Aug 18, 2026): Exercise/Conversion of 40,000 VRDN shares, $528.4K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 18, 2026 | Viridian Therapeutics, Inc.\DE (VRDN) | Exercise/Conversion | 40,000 | $528.4K |
| May 5, 2026 | Terns Pharmaceuticals, Inc. (TERN) | Disposition to Issuer | 64,000 | n/a |
| Mar 4, 2026 | Viridian Therapeutics, Inc.\DE (VRDN) | Grant/Award | 95,800 | n/a |
| Feb 2, 2026 | Terns Pharmaceuticals, Inc. (TERN) | Grant/Award | 1,697 | n/a |
| Jun 12, 2025 | Terns Pharmaceuticals, Inc. (TERN) | Grant/Award | 45,000 | n/a |
| Mar 12, 2025 | Viridian Therapeutics, Inc.\DE (VRDN) | Grant/Award | 310,700 | n/a |
| Feb 4, 2025 | Terns Pharmaceuticals, Inc. (TERN) | Grant/Award | 10,657 | n/a |
| Jul 2, 2024 | Terns Pharmaceuticals, Inc. (TERN) | Grant/Award | 4,676 | n/a |
| Jun 14, 2024 | Terns Pharmaceuticals, Inc. (TERN) | Grant/Award | 32,000 | n/a |
| Jun 14, 2023 | Terns Pharmaceuticals, Inc. (TERN) | Grant/Award | 32,000 | n/a |